18 Nov 2025 | 5 Mins Read
Mankind Pharma impacted by domestic slowdown and GST transition
Flipitmoney
Mankind Pharma, India's fourth-largest drugmaker, saw a 21% year-on-year fall in net profit due to rising financing costs and depreciation linked to the acquisition of Bharat Serums and Vaccines. Domestic sales growth slowed to 6.6%, attributed to GST 2.0 disruptions and monsoon issues. The company expects export growth to remain robust and a recovery in the second half.